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RESISTANCE TO THERAPY IN MATURE 
PALMERSTON NORTH MICE TREATED WITH 
CYCLOPHOSPHAMIDE OR HYDROCORTISONE 
SODIUM SUCCINATE 
SARA ELLEN WALKER and BERTRAM SCHNITZER 
Inbred Palmerston North (PN) mice are a newly 
recognized model of systemic lupus erythematosus. In 
this study PN mice with established autoimmune dis- 
ease were treated until death with cyclophosphamide (8 
mg/kg/day) or hydrocortisone (10 mg/kg/day). These 
doses had previously been found to prevent or suppress 
disease in another lupus model, the NZB/NZW mouse. 
In the PN strain, autoantibodies, severity of glomerulo- 
nephritis, and longevity were not influenced by treat- 
ment. Furthermore, the incidence of neoplasms was not 
increased in P N  mice receiving prolonged therapy with 
immunosuppressive drugs. Unlike NZB/NZW mice, P N  
mice were resistant to the effects of cyclophosphamide 
and hydrocortisone. 
Inbred mice of the Palmerston North (PN) strain 
spontaneously develop a disease similar to systemic 
lupus erythematosus (SLE) in humans. These animals 
have positive indirect immunofluorescent tests for anti- 
nuclear antibodies (ANA), antibodies to DNA (anti- 
DNA), LE cells, glomerulonephritis, and arteritis (1). 
The availability of this newly recognized strain of au- 
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toimmune mice provided an opportunity to treat their 
lupus-like disease with immunosuppressive drugs. 
Earlier studies showed that alkylating agents and 
corticosteroids were effective in treating autoimmune 
disease in another animal model of SLE, the hybrid 
New Zealand Black/New Zealand White (NZB/NZW) 
mouse. When mature NZB/NZW mice with active dis- 
ease received cyclophosphamide or betamethasone, au- 
toantibody production and glomerulonephritis were 
suppressed (2,3). Furthermore, an increased incidence 
of neoplasms was observed in NZB/NZW mice with es- 
tablished disease, which had received prolonged treat- 
ment with cyclophosphamide (43). 
In the current study the immunosuppressive ef- 
fects and oncogenic properties of cyclophosphamide 
and hydrocortisone were investigated in a mouse strain 
that was genetically different from New Zealand mice. 
PN mice with established autoimmune disease received 
lifelong therapy with immunosuppressive doses of cy- 
clophosphamide or hydrocortisone. Glomerulonephritis 
was suppressed in cyclophosphamide-treated PN fe- 
males, but therapy did not control autoantibody pro- 
duction or increase longevity in mice of either sex. Oc- 
currence of neoplasms did not increase in treated mice. 
It was concluded that two drugs which suppressed es- 
tablished autoimmune disease in New Zealand mice 
were not effective in treating the lupus-like disease of 
mature PN mice. 
MATERIALS AND METHODS 
Animals, Mice used in this study were inbred descend- 
ents of PN mice in F27-F30 generations obtained from Dr. 
Richard D. Wigley in Palmerston North, New Zealand, in 
March 1974 (1). Two groups of mice were treated: Group I- 
sixty-two PN mice (32 females and 30 males) in generations 
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F28-F31 were entered in the study in November 1974. These 
mice, descended from stock that carried chronic respiratory 
disease (6), were kept in conventional animal quarters. Group 
11--fifty-seven mice (27 females and 30 males) in F35-F37 
generations were born and housed in a laminar flow hood. 
Group I1 mice were the offspring of F34 PN mice which had 
been delivered by cesarean section and raised on pathogen- 
free CD- I mothers (Charles River Laboratories, Portage 
Michigan) in a laminar flow hood. Group I1 mice entered the 
study in February 1977. 
Animals used in these experiments were maintained in 
facilities fully accredited by the American Association for Ac- 
creditation of Laboratory Animal Care. Experiments were 
conducted according to the Guide for the Care and Use of Lab- 
oratory Animals. 1972, Institute for Laboratory Animal Re- 
sources, National Research Council--National Academy of 
Science. 
Treatment protocol. Littermates aged 22 to 28 weeks 
were divided at random into control or treatment groups. It 
was assumed that these mature animals had active autoim- 
mune disease. Earlier studies in this laboratory showed that 
PN mice uniformly developed glomerular deposits of immu- 
noglobulin and complement after one month of age, and anti- 
DNA antibodies were found in sera from 72% of PN mice at 
the age of 5-6 months (1). Twenty Group I mice (10 females, 
10 males) and 20 Group I1 mice (10 females, 10 males) re- 
ceived daily subcutaneous injections of 0. I ml 0.15M NaCI. 
Twenty Group I mice (10 females, 10 males) and 18 Group I1 
mice (7 females, 1 1  males) were subcutaneously injected with 
cyclophosphamide, 8 mg/kg/day, which was dissolved in 0. I 
ml 0.15M NaCl immediately before use. This dose of cyclo- 
phosphamide was chosen because i t  suppressed autoimmune 
disease in NZB/NZW mice (7). Twenty Group I mice (10 fe- 
males, 10 males) and 2 1 Group I1 mice (10 females, 11  males) 
received subcutaneous injections of hydrocortisone sodium 
succinate (Upjohn Company, Kalamazoo, Michigan), 10 mg/ 
kg/day. In an earlier study in this laboratory, this treatment 
regimen prevented glomerulonephritis and prolonged life- 
spans in young female NZB/NZW mice (8). 
Mice were bled from the orbital plexus before treat- 
ment and after 24 and 52 weeks of treatment. Terminal blood 
samples were obtained from 48 mice. Sera for ANA tests and 
anti-DNA determinations were stored in sealed capillary 
tubes at -20°C. At each bleeding, leukocytes were counted in 
the conventional manner and blood films were prepared and 
stained with Wright’s stain. Differential counts of 100 white 
blood cells (WBC) on each slide were performed. 
Therapy continued until death. Mice were examined 
daily, and animals were killed when they appeared moribund 
or developed palpable masses. Complete postmortem exami- 
nations were performed according to a protocol described in 
another publication (9). 
Histologic studies. Tissue sections stained with hema- 
toxylin and eosin were examined for infection, neoplasia, and 
vasculitis. Severity of renal disease was scored by counting the 
number of abnormalities in 20 glomeruli in a 4p cross section 
of each kidney. This method has been used to assess severity 
of glomerulonephritis in groups of NZB/NZW mice which re- 
ceived either saline (controls) or therapy with immuno- 
suppressive drugs (8). 
Autoantibadies. Undiluted serum was tested for heter- 
ogeneous ANA on guinea pig liver substrate, by use of an in- 
direct immunofluorescent method (1). A modification of the 
Farr technique was used to measure specific anti-DNA anti- 
bodies. This assay quantitated the percentage of l4 C-labeled 
KB cell-derived DNA bound by 0.015 ml of heat-inactivated 
mouse serum (7). In this laboratory, values greater than 20% 
are positive for anti-DNA. 
Statistical analysis. Student’s t test and chi-square 
tests were performed as described by Snedecor and Cochran 
(10). 
RESULTS 
Longevity. Mean ages at death in control and 
treated mice are listed in Table 1. Based upon observa- 
tions of 203 PN mice in this laboratory (l), it was ex- 
pected that untreated female PN mice would die pre- 
maturely with renal disease and vasculitis. In the 
current therapeutic study, mean longevity was 53 weeks 
(+ 4 SE) in female control mice and 65 weeks (* 5) in 
male control mice. The difference in mean longevity in 
untreated mice of both sexes was not significant (P > 
0.05). Mean lifespans were similar in treated and con- 
trol mice of both sexes, and therapy with cyclophospha- 
mide or hydrocortisone did not increase longevity in PN 
mice. 
Twenty-one mice died of infections when they 
were 28 to 83 weeks of age. Most of these animals had 
glomerulonephritis and/or arteritis. Premature deaths 
of infected mice did not influence mean longevity in 
groups of control or treated mice. When infected mice 
were deleted from longevity figures, mean lifespans 
were: control mice-females 5 1, males 67; cyclophos- 
phamide-treated mice-females 56, males 6 1; hydro- 
cortisone-treated mice-females 63, males 57 weeks. 
Causes of death. Postmortem examinations 
showed that renal disease and vasculitis caused death in 
23 of 40 control mice (Table 2). Treatment did not re- 
verse autoimmune disease in PN mice. Death was at- 
tributed t o  glomerulonephritis and arteritis in 15 of 38 
Table 1. Mean ages at death in control and treated PN mice 
_ _  -. 
Females Males 
Control* 53  * 4 t  65 f 5 
(20) (17) 
58*3 5 9 * 4  CyclophosphamideS 
(18) (19) 
Hydrocortisone$ 65 + 4  57 f 5 
_. (17) (17) 
* 0.1 ml 0.15M NaCl/day by subcutaneous injection. 
t Mean weeks of age at death f SE. Parentheses enclose numbers of 
mice in each group which were examined postmortem. Mice dying of 
iatrogenic causes or lost by autolysis were excluded from this table. 
# 8 mg/kg/day by subcutaneous injection. 
$ 10 mg/kg/day by subcutaneous injection. 
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Table 2. Causes of death in control and treated PN mice 
Renal 
disease, Pulmonary 
vasculitis Infection* Neoplasm Hydronephrosis edema Hemorrhage Othert Total 
Con t r o 1 s 
F e m a 1 e s 16 2 1 0 0 0 1 20 
Males 7 6 2 1 0 0 4 20 
Females 10 5 1 0 0 1 I 18 
Males 5 6 0 0 5 1 3 20 
Females 12 2 3 0 0 0 4 21 
Males 11 0 1 3 0 0 5 20 
Cyclophosphamide 
Hydrocortisone 
* Death from infection occurred only in Group I mice, which were maintained in conventional animal quarters. Group I1 mice in a laminar flow 
hood did not die with infections. 
t This category includes mice which died of iatrogenic causes during routine orbital bleeding (4) and mice lost by autolysis (8). In 6 instances (2 
control mice, 3 cyclophosphamide-treated mice, 1 hydrocortisone-treated mouse) there was minimal evidence of autoimmune disease and the cause 
of death could not be determined. 
mice receiving cyclophosphamide and 23 of 41 mice re- 
ceiving hydrocortisone. Group I mice, which were 
housed in the conventional manner, had a high in- 
cidence of infections. Twenty-one of 62 Group I mice 
died with purulent pneumonia, bronchiectasis, pyelone- 
phritis, or abscesses. In contrast to group I mice, no in- 
fections were found in “clean” Group I1 mice in a lami- 
nar flow hood. An important finding was the small 
number of neoplasms in PN mice treated with cyclo- 
phosphamide or hydrocortisone. Based upon earlier ex- 
perience with NZB/NZW mice, it was assumed that 
prolonged immunosuppressive therapy was oncogenic 
in mice with autoimmune disease (8,9). In the current 
study, neoplasms were distributed equally among con- 
trol mice (2 lymphomas, one sarcoma), cyclophospha- 
mide-treated mice (one lymphoma), and hydro- 
cortisone-treated mice (3 sarcomas, one squamous cell 
carcinoma). Three neoplasms arose in Group I mice, 
and 5 neoplasms were found in Group I1 mice. 
Autoantibodies. Positive tests for heterogeneous 
ANA are listed in Table 3. In control mice, numbers of 
positive tests increased with age. Twenty-four weeks af- 
Table 3. Autoantibodies in control and treated PN mice 
Weeks of treatment 



























2 1 f 2  
23 f 1 
23 f 1 
23 f 1 
22 f 1 







26 r+- 3 
27 f 2 
21 f 2 
22 f 1 
34 f 3 







36 f 2 
21 f 2 
3 5 f 2  
3 2 f 3  
27 f 3 







29 f 3 
27 f 2 
29 f 2 
2 5 f 2  
2 5 * 2  
21 f 2 
* Percent of mice with positive indirect immunofluorescent tests for ANA. 
t Mean f SE. A modification of the Farr technique was used to test sera for specific antibodies to DNA. 
Values are expressed as percent of I4C-labeled DNA bound to 0.015 ml of mouse serum. 
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ter the study began, positive ANA tests were found in 
100% of control female mice and 69% of control male 
mice. In the cyclophosphamide treatment group, age- 
dependent increases in numbers of positive tests were 
similar to untreated control mice. When hydro- 
cortisone-treated mice were bled 24 to 52 weeks after 
the study began, numbers of positive ANA tests in male 
mice were decreased compared to control mice. This 
trend suggested that hydrocortisone therapy suppressed 
ANA response in male PN mice. However, chi-square 
analysis showed that numbers of positive tests were not 
decreased significantly in treated animals compared to 
controls. 
During the 52-week period of observation, mean 
anti-DNA antibody levels increased from 27 to 36% in 
female control mice. Mean anti-DNA values did not in- 
crease with age in untreated male mice.While PN mice 
of both sexes received prolonged treatment with cyclo- 
8.0 r 
phosphamide or hydrocortisone, anti-DNA levels re- 
mained similar to controls (Table 3). 
WBC counts. Serial WBC counts in control and 
treated mice at 0, 24, and 52 weeks are illustrated in 
Figure 1. At the start of the study, mean peripheral 
WBC counts were 5036 (2  344) in female control mice 
and 7812 (* 597) in male control mice. Modest age-re- 
lated decreases of circulating leukocytes were noted in 
control mice of both sexes. After 24 weeks of treatment, 
mice receiving cyclophosphamide had significant sup- 
pression of WBC counts compared to corresponding 
control mice (for females P -= 0.005; for males P < 
0.005). Suppressed peripheral WBC persisted after 52 
weeks of cyclophosphamide therapy. At this point in the 
study, differences in mean leukocyte counts in cyclo- 
phosphamide-treated male PN mice compared to con- 
trols were significant at the 0.05 level. Treatment with 
hydrocortisone for 24 weeks was associated with signifi- 
Lymphocytes in 9 
C Cy HSS C Cy HSS C Cy HSS 
0 24 52 
WEEKS OF TREATMENT 
Figure 1. This graph illustrates mean white blood cell (WBC) counts and absolute lymphocyte counts (cells/ 
mm’) in PN mice at the start of treatment and after 24 and 52 weeks of treatment with cyclophosphamide 
(Cy) or hydrocortisone sodium succinate (HSS). Control mice (C) received saline. Each bar represents the 
mean total WBC count for a group of mice; shaded areas indicate mean absolute lymphocyte counts. Twenty- 
four weeks after the study began, WBC counts and lymphocyte counts in both groups of treated mice were 
depressed significantly compared to corresponding control mice. After 52 weeks, significant suppression of 
WBC counts and lymphocyte counts persisted in male mice that were treated with cyclophosphamide or hy- 
drocortisone. 
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Glomerular Periarterial (P < 0.001) and male mice (P -= 0.001) compared to fe- 
male and male control mice. In the 15 hydrocortisone- lesions* lymphocytest ArteritisS 
treated mice which survived until week 52 of the study, 
leukocytes were suppressed. In male mice in this treat- 
ment group, the mean WBC count at 52 weeks was de- 
creased significantly compared to control mice (P < 
Controls 
Females 3 3 + 3  3 (M) 3/20 
Males 25 f 3 2 ( M )  4/17 
0.05). Females 20 f 2s 0 (0-2) 1/18 
Mean absolute lymphocyte counts are repre- Males 19 f 2 0 (0-1) 1/19 
Females 32 f 3 2 1/18 sented by shaded areas within the bars in Figure 1. In 
control mice, lymphocyte counts fell during the first Males 21 f 3 O(0-3)  0/15 
year of the study. In mice receiving cyclophosphamide 
or hydrocortisone, selective losses of lymphocytes ac- 
counted for most of the leukopenia observed after 24 
Cyclophosphamide 
Hydrocortisone 
* Mean number of abnormalities counted in 20 glomeruli f SE. 
t Median (range). Periarterial lymphocytes were scored on a scale of 0 
to4+. 
and 52 weeks of treatment. 
Renal histology. Table 4 lists mean glomerular 
lesion scores and vascular abnormalities in kidneys 
from 107 control and treated mice. In untreated mice, 
mesangial thickening and hypercellularity, basement 
membrane thickening, glomerular hypercellularity, and 
fibrinoid degeneration were reflected in mean glomeru- 
lar lesion scores of 33 (+- 3) in females and 25 (& 3) in 
males. Periarterial infiltrates were common, and fibrin- 
oid necrosis of renal arteries occurred in 19% of control 
mice. In female mice treated with cyclophosphamide, 
the mean glomerular lesion score of 20 (& 2) was sup- 
pressed significantly compared to control female mice 
(P < 0.01). Periarterial lymphocytes were rare, and the 
incidence of renal arteritis was 5%. In contrast to the cy- 
clophosphamide treatment group, mice that received 
hydrocortisone had renal lesions similar to untreated 
control mice. 
DISCUSSION 
This report describes resistance to immuno- 
suppressive therapy in a strain of inbred mice which 
spontaneously develop autoantibodies and glomerulo- 
nephritis. The serologic and histologic abnormalities in 
PN mice closely resemble SLE in humans, and they 
represent a new murine model of lupus (1). A recent re- 
port described ANA in sera from PN mice at 5 months 
of age, and 80% of PN mice were ANA-positive at the 
age of 10 months. Anti-DNA were found in sera from 
76% of PN mice when they were 10 months old. Depos- 
its of immunoglobulins and complement appeared in 
renal glomeruli at 2 to 4 weeks of age, and examination 
of renal tissue by electron microscopy showed thick glo- 
merular basement membranes and dense intra- 
membranous deposits. Mean ages at death were 11.6 
months in female mice and 15.8 months in male mice. 
.. + Number of kidneys with arteritis/number of kidneys examined. 
8 Compared to female control mice, P < 0.01. 
The most common causes of death were glomerulone- 
phritis and arteritis (1). 
Earlier therapeutic studies showed that estab- 
lished autoimmune disease in NZB/NZW mice re- 
sponded to treatment with cyclophosphamide or hydro- 
cortisone. When 5-month-old female NZB/NZW mice 
received cyclophosphamide 4.5 mg/kg/day for 3 
months, autoantibody levels were suppressed and life- 
spans were prolonged (2). Treatment with the cortico- 
steroid drug, betamethasone, suppressed antinuclear 
antibodies and glomerulonephritis in adult female New 
Zealand mice; therapy was begun when the mice were 5 
to 6.5 months of age (3). In the current study, treatment 
was started after autoimmune disease was established in 
PN mice. These animals received doses of cyclophos- 
phamide and hydrocortisone which were effective in 
preventing glomerulonephritis and prolonging lifespans 
in NZB/NZW mice (73). However, careful monitoring 
of longevity, autoantibodies, and renal histology in con- 
trol and treated mice showed that treatment failed to al- 
ter the course of disease in PN mice. 
The poor response to therapy in PN mice com- 
pared to New Zealand mice may reflect different rates 
of drug metabolism and turnover in two genetically dif- 
ferent strains of mice. However, the striking suppression 
of total WBC and lymphocyte counts in PN mice 
treated with cyclophosphamide or hydrocortisone pro- 
vided evidence that levels of both drugs were capable of 
controlling bone marrow activity. It is also possible that 
established autoimmune disease in PN mice is unusu- 
ally resistant to treatment. Additional experiments 
would be required to determine if therapeutic inter- 
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vention at an early age can prevent renal disease and 
prolong life in PN mice. 
Earlier studies in this laboratory provided evi- 
dence that cyclophosphamide was oncogenic in NZB/ 
NZW mice. When 20 hybrid New Zealand mice aged 4 
to 24 weeks received life-long treatment with cyclophos- 
phamide, 8 mg/kg/day, neoplasms appeared in 17 
mice. Seven animals, aged 17 to 22 weeks when the 
study began, were considered to have established au- 
toimmune disease at the start of therapy (1 1). All 7 of 
these mature mice developed neoplasms after 58 to 108 
weeks of treatment. The pattern of oncogenesis was the 
same in mice which were either young or mature at the 
beginning of the study (9). The oncogenic properties of 
cyclophosphamide in NZB/NZW mice with active dis- 
ease have been recorded by other investigators. Russell 
and Hicks (4) treated 192 female NZB/NZW mice aged 
120-200 days with cyclophosphamide, 1.8 mg/mouse/ 
week. Twenty-nine percent of the treated mice devel- 
oped neoplasms. In another therapeutic study, tumor 
incidence of 22 percent was observed when female 
NZB/NZW mice aged 6 to 12 months received daily or 
intermittent doses of cyclophosphamide (5). 
The current therapeutic study ,.tilizing PN mice 
showed that oncogenesis is not an inev, table complica- 
tion of prolonged therapy of autoimmun? disease. Suc- 
cessful suppression of disease appears to :orrelate with 
increased numbers of neoplasms. In NZB,'NZW mice 
with active disease, cyclophosphamide ti. erapy in- 
creased longevity and accelerated appearancc of neo- 
plasms (43). In the current study, the failure to control 
autoimmune disease in PN mice was associated with a 
low incidence of neoplasms in treated animals. 
Another factor that may be associated with drug- 
induced tumors in mice is the presence of potentially 
oncogenic type C viruses. These viruses are demon- 
strated by electron microscopy in lymphatic tissues of 
New Zealand mice (12), and they are cultured from 
NZB/NZW mouse cells (1 3). Expression of xenotropic 
type C viruses in NZB mice is a genetically controlled 
trait (14). In this laboratory, we have not been able to 
identify type C viral particles by electron microscopy in 
thymic tissue from 7 adult PN mice (unpublished data). 
Results of this preliminary study did not exclude the 
possibility that PN mice carry type C viruses. Never- 
theless, it may be postulated that PN mice lack the ge- 
netically determined ability to produce large numbers 
of type C viruses. In the chronically immunosuppressed 
state, the inability to generate oncogenic viruses may 
protect an animal from the appearance of neoplasms. 
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